Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Hereditary Angioedema Therapeutic Market: By Drug Class: C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others; By Treatment Type; By Route of Administration; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Hereditary Angioedema Therapeutic Market Outlook

The global hereditary angioedema therapeutic market was estimated at USD 2.7 billion in 2020 and is predicted to grow at a CAGR of 8.7% in the forecast period of 2021-2026 to achieve USD 4.5 billion by 2026.

 

Global Hereditary Angioedema Therapeutic Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Globally, the rising cases of hereditary angioedema (HAE) is a key driver of the market. The condition affects between 1-9 individuals per 100,000 population, according to the National Organization for Rare Disorders (NORD). Due to underreporting and misdiagnosis, the actual number of people with the condition is significantly higher.

 

Properties and Applications

The hereditary angioedema therapeutic industry can be divided based on segments like drug class, treatment type, and route of administration.

 

Global Hereditary Angioedema Therapeutic Market By Treatment Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry can be broadly categorised based on drug class into:

  • C1-Esterase Inhibitor 
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

The industry can be divided based on treatment types as:

  • Prophylaxis Treatment
  • On-Demand Treatment

The industry can be classified based on the route of administration:

  • Intravenous
  • Subcutaneous
  • Oral

The EMR report looks into the regional markets of hereditary angioedema therapeutic like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific regions.

 

Global Hereditary Angioedema Therapeutic Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The hereditary angioedema therapeutic market is being driven by the increasing awareness-raising activities among the general population. The lack of awareness of hereditary angioedema therapeutic is the main reason for misdiagnosis, which in turn results in patients receiving insufficient care. Some patients with hereditary angioedema are misdiagnosed with appendicitis, gastrointestinal disorders, and other non-allergic angioedema conditions. A small number of patients misdiagnosed for the disorder provides a large pool of patients with significant medical needs. This is expected to be a key market driver for hereditary angioedema therapeutic in the coming years.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global hereditary angioedema therapeutic market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Shire Plc (Takeda)
  • BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
  • Ionis Pharmaceuticals, Inc. 
  • Pharming Group N.V.
  • CSL Limited 
  • Attune Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc. 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Treatment Type , Route of Administration, Region
Breakup by Drug Class C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others
Breakup by Treatment Type Prophylaxis Treatment, On-Demand Treatment
Breakup by Route of Administration Intravenous, Subcutaneous, Oral
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Shire Plc (Takeda), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX),
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Pharming Group N.V. (AMS: PHARM),
CSL Limited (ASX: CSL), Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc. (NASDAQ: ADVM), Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

Key Questions Answered in the Market Report

  • How has the global hereditary angioedema therapeutic market performed in the previous years (2016-2020)?
  • What is the forecast assessment of the market for 2021-2026?
  • What are the major drivers of the historical (2016-2020) and forecast (2021-2026) periods?
  • What are the major constraints of the historical (2016-2020) and forecast (2021-2026) periods?
  • What are the major demand indicators of the global market?
  • What are the import and export trends in the global hereditary angioedema therapeutic market?
  • Who are the top importers and exporters of hereditary angioedema therapeutic in the industry globally?
  • Who are the key manufacturers in the global hereditary angioedema therapeutic market?
  • What is the degree of competition in the global market?
  • What are the major events and developments taking place within the global industry?

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Hereditary Angioedema Therapeutic Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Hereditary Angioedema Therapeutic Historical Market (2016-2020) 
    8.3    Global Hereditary Angioedema Therapeutic Market Forecast (2021-2026)
    8.4    Global Hereditary Angioedema Therapeutic Market by Drug Class
        8.4.1    C1-Esterase Inhibitor
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Bradykinin B2 Receptor Antagonist
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
        8.4.3    Kallikrein Inhibitor
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2016-2020)
            8.4.3.3    Forecast Trend (2021-2026)
        8.4.4    Others
    8.5    Global Hereditary Angioedema Therapeutic Market by Treatment Type
        8.5.1    Prophylaxis Treatment
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2016-2020)
            8.5.1.3    Forecast Trend (2021-2026)
        8.5.2    On-Demand Treatment
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2016-2020)
            8.5.2.3    Forecast Trend (2021-2026)
    8.6    Global Hereditary Angioedema Therapeutic Market by Route of Administration
        8.6.1    Intravenous
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2016-2020)
            8.6.1.3    Forecast Trend (2021-2026)
        8.6.2    Subcutaneous
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2016-2020)
            8.6.2.3    Forecast Trend (2021-2026)
        8.6.3    Oral
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2016-2020)
            8.6.3.3    Forecast Trend (2021-2026)
    8.7    Global Hereditary Angioedema Therapeutic Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Shire PLC
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    BioCryst Pharmaceuticals, Inc.
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Ionis Pharmaceuticals, Inc.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Pharming Group N.V.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    CSL Limited.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Attune Pharmaceuticals, Inc.
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Others
13    Industry Events and Developments


List of Figures and Tables

1.    Global Hereditary Angioedema Therapeutic Market: Key Industry Highlights, 2016 and 2026
2.    Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Drug Class (USD Million), 2016-2020
3.    Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Drug Class (USD Million), 2021-2026
4.    Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Treatment Type (USD Million), 2016-2020
5.    Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Treatment Type (USD Million), 2021-2026
6.    Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Route Of Administration (USD Million), 2016-2020
7.    Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Route of Administration (USD Million), 2021-2026
8.    Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Region (USD Million), 2016-2020
9.    Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Region (USD Million), 2021-2026
10.    North America Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Million), 2016-2020
11.    North America Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Million), 2021-2026
12.    Europe Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Million), 2016-2020
13.    Europe Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Million), 2021-2026
14.    Asia Pacific Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Million), 2016-2020
15.    Asia Pacific Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Million), 2021-2026
16.    Latin America Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Million), 2016-2020
17.    Latin America Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Million), 2021-2026
18.    Middle East and Africa Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Million), 2016-2020
19.    Middle East and Africa Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Million), 2021-2026
20.    Global Hereditary Angioedema Therapeutic Market Structure

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER